Debriefing ACC 2026: Key Cardiovascular Trials and Their Clinical Implications for Pharmacists
Craig Beavers and Kyle Fischer debrief on key late-breaking cardiovascular trials from the 2026 American College of Cardiology Scientific Sessions.
In this episode of The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, welcomes back Kyle Fischer, PharmD, MBA, BCCP, a cardiology clinical pharmacy specialist at Ascension Medical Center Austin at Dell Medical School in Austin, Texas, to debrief on late-breaking trials from the 2026 American College of Cardiology (ACC) Scientific Sessions. Fischer, a PGY-2–trained cardiology pharmacist, shifts roles from previewer to debriefer as the two discuss the clinical significance of key studies and their implications for cardiovascular pharmacotherapy.
Beavers and Fischer review 5 trials from ACC 2026, emphasizing shared decision-making and the evolving landscape of cardiovascular pharmacotherapy throughout their discussion.































































































































